Abrar Softah, Moureq R Alotaibi, Ali R Alhoshani, Tareq Saleh, Khalid Alhazzani, Mashal M Almutairi, Raed AlRowis, Samiyah Alshehri, Norah A Albekairy, Hisashi Harada, Rowan Boyd, Eesha Chakraborty, David A Gewirtz, Homood M As Sobeai
Despite significant advances in the treatment of triple-negative breast cancer, this disease continues to pose a clinical challenge, with many patients ultimately suffering from relapse. Tumor cells that recover after entering into a state of senescence after chemotherapy or radiation have been shown to develop a more aggressive phenotype, and to contribute to disease recurrence. By combining the PARP inhibitor (PARPi), talazoparib, with radiation, senescence was enhanced in 4T1 and MDA-MB-231 triple-negative breast cancer cell lines (based on SA-β-gal upregulation, increased expression of CDKN1A and the senescence-associated secretory phenotype (SASP) marker, IL6 )...
November 16, 2023: Biomedicines